FDA Expands Guselkumab Label in PsA - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

  • By

  • Kathryn Wighton

  • May 29, 2026

  • 2 min

Share

Clinical Scorecard: FDA Expands Guselkumab Label in PsA

At a Glance

CategoryDetail
ConditionActive Psoriatic Arthritis (PsA)
Key MechanismsInhibition of structural joint damage progression
Target PopulationAdults with active psoriatic arthritis at risk for joint damage
Care SettingOutpatient care for biologic-naïve patients

Key Highlights

  • Guselkumab approved for inhibition of structural joint damage in PsA
  • Supported by phase 3b APEX trial results
  • 57% reduction in radiographic progression from weeks 24 to 48 for patients switching from placebo
  • No new safety signals identified
  • Only interleukin-23 inhibitor with structural inhibition in US prescribing information

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of PsA based on clinical criteria and imaging

Management

  • Guselkumab as a treatment option for patients with inadequate response to standard therapies

Monitoring & Follow-up

  • Monitor for joint symptoms and progression of structural damage

Risks

  • Potential for irreversible joint damage if untreated

Patient & Prescribing Data

Biologic-naïve adults with active PsA

Guselkumab shows significant efficacy in reducing joint symptoms and structural damage

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    FDA Expands Guselkumab Label in PsA

    • by Kathryn Wighton

    • May 29, 2026

    Related Content

    Medical Oddities: Tattoos and Teeth Share Work Struggles

    From unexpected workplace parallels to kitchen-counter experiments and a few clinical twists, this set of stories covered more ground than your average shift.

    Combination Therapy Shows Potential in Psoriasis, Obesity

    Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

    AI Scribes Lag Clinicians on Note Quality

    A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness